Awaiting FDA nod, Novartis touts latest data on gene therapy Zolgensma

6th May 2019 Uncategorised 0

As Novartis waits for FDA action on its gene therapy Zolgensma, expected this month, the company has rolled out yet another round of data on the spinal muscular atrophy treatment.

More: Awaiting FDA nod, Novartis touts latest data on gene therapy Zolgensma
Source: fierce